≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other specific arthropathies

DOID Endpoint Browser PheWeb

M13_OTERSPECARTHR

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M12.8
  • Hospital discharge: ICD-9 — 7164
  • Cause of death: ICD-10 — M12.8
  • Cause of death: ICD-9 — 7164

2 out of 7 registries used, show all original rules.

74

4. Check minimum number of events

None

74

5. Include endpoints

None

74

6. Filter based on genotype QC (FinnGen only)

72

Control definitions (FinnGen only)

Control exclude
M13_ARTHROPATHIES

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M12
Name in latin
Aliae arthropathiae specificae non alibi classificatae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 538 264 268
Only index persons 487 239 248
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 43.11 48.62 37.31
Only index persons 39.19 46.04 32.59

-FinnGen-

Key figures

All Female Male
Number of individuals 72 41 31
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 49.25 51.96 45.66

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
74
Matched controls
740
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M12.8
ICD-10 Finland
Other specific arthropathies, not elsewhere classified
+∞
75.4
59
*
7164A
ICD-9 Finland
Other and unspecified arthropathies, Transient arthropathy
+∞
16.2
15
*
M19.0
ICD-10 Finland
Primary arthrosis of other joints
38.8
14.7
18
6
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
21.9
14.5
21
13
M13.9
ICD-10 Finland
Arthritis, unspecified
61.7
13.4
15
*
L04AX03
ATC
methotrexate; systemic
19.3
12.1
18
12
A07EC01
ATC
sulfasalazine; oral, rectal
26.3
11.2
15
7
M25.5
ICD-10 Finland
Pain in joint
5.3
11.0
32
93
P01BA02
ATC
hydroxychloroquine; oral
28.2
10.7
14
6
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
+∞
10.7
10
*
M17.1
ICD-10 Finland
Other primary gonarthrosis
20.5
10.4
15
9
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
31.0
10.2
13
5
M23.2
ICD-10 Finland
Derangement of meniscus due to old tear or injury
57.0
8.9
10
*
NGF25
NOMESCO Finland
Operation for osteochondritis of knee, arthroscopic
57.0
8.9
10
*
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
15.3
8.8
14
11
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
31.8
8.8
11
*
L01BA01
ATC
methotrexate; systemic
101.1
8.6
9
*
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
+∞
8.5
8
*
M16.1
ICD-10 Finland
Other primary coxarthrosis
38.0
8.3
10
*
NGF15
NOMESCO Finland
Total synovectomy of knee, arthroscopic
+∞
7.4
7
*
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
+∞
7.4
7
*
L88
ICPC
Rheumatoid/seropositive arthritis
44.2
6.9
8
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
10.8
6.6
12
13
NFB30
NOMESCO Finland
Primary total prosthetic replacement of hip joint not using cement
76.1
6.5
7
*
Z96.6
ICD-10 Finland
Presence of orthopaedic joint implants
76.1
6.5
7
*
NGB40
NOMESCO Finland
Primary total prosthetic replacement of knee joint with patellar part - sliding prosthesis
+∞
6.3
6
*
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
+∞
6.3
6
*
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
+∞
6.3
6
*
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
9.3
6.1
12
15

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Orthopedic Surgery
20 [38004465]
2.2e+00
2.7e+00
—
1.0e+50
—
2.6e+00
1.9e+00
cases:26.56%
controls:3.91%
cases:18.75%
controls:1.56%
—
—
cases:20.31%
controls:0.00%
—
—
cases:25.40%
controls:2.39%
cases:35.00%
controls:7.73%
17
25
47
614
12
10
52
629
—
13
0
51
639
—
16
15
47
613
21
45
39
537
Internal Medicine
11 [38004456]
9.2e-01
1.9e+00
—
—
3.1e+00
2.0e+00
1.2e+00
cases:29.69%
controls:14.40%
cases:31.25%
controls:6.26%
—
—
—
—
cases:15.63%
controls:0.78%
cases:26.98%
controls:4.94%
cases:36.67%
controls:14.26%
19
92
45
547
20
40
44
599
—
—
10
5
54
634
17
31
46
597
22
83
38
499
codeine and paracetamol
N02AJ06 [1123647]
1.5e+00
2.4e+00
—
—
—
2.1e+00
1.2e+00
cases:25.00%
controls:7.20%
cases:20.31%
controls:2.19%
—
—
—
—
—
—
cases:19.05%
controls:2.71%
cases:21.67%
controls:7.73%
16
46
48
593
13
14
51
625
—
—
—
12
17
51
611
13
45
47
537
prednisolone
A07EA01 [21600653]
1.6e+00
1.9e+00
—
—
—
2.1e+00
1.4e+00
cases:20.31%
controls:4.69%
cases:9.38%
controls:1.56%
—
—
—
—
—
—
cases:11.11%
controls:1.43%
cases:23.33%
controls:6.87%
13
30
51
609
6
10
58
629
—
—
—
7
9
56
619
14
40
46
542
prednisolone; oral, parenteral
H02AB06 [21602734]
1.6e+00
1.9e+00
—
—
—
2.1e+00
1.4e+00
cases:20.31%
controls:4.69%
cases:9.38%
controls:1.56%
—
—
—
—
—
—
cases:11.11%
controls:1.43%
cases:23.33%
controls:6.87%
13
30
51
609
6
10
58
629
—
—
—
7
9
56
619
14
40
46
542
Outpatient Visit
OP [9202]
6.1e-01
9.7e-01
9.2e-01
—
1.2e+00
1.5e+00
1.4e+00
cases:68.75%
controls:54.46%
cases:60.94%
controls:37.25%
cases:17.19%
controls:7.67%
—
—
cases:20.31%
controls:7.20%
cases:66.67%
controls:30.25%
cases:86.67%
controls:61.34%
44
348
20
291
39
238
25
401
11
49
53
590
—
13
46
51
593
42
190
21
438
52
357
8
225
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
1.4e+00
1.4e+00
1.8e+00
—
—
1.5e+00
1.1e+00
cases:18.75%
controls:5.48%
cases:20.31%
controls:5.79%
cases:7.81%
controls:1.41%
—
—
—
—
cases:20.63%
controls:5.57%
cases:21.67%
controls:8.08%
12
35
52
604
13
37
51
602
5
9
59
630
—
—
13
35
50
593
13
47
47
535
Physical Medicine And Rehabilitation
25 [38004468]
—
—
—
—
—
2.4e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.96%
cases:16.67%
controls:3.44%
—
—
—
—
—
6
6
57
622
10
20
50
562
Thorax X-ray examination
GD1AA [2001303617]
1.3e+00
—
—
—
—
2.4e+00
1.6e+00
cases:14.06%
controls:4.23%
—
—
—
—
—
—
—
—
cases:11.11%
controls:1.11%
cases:15.00%
controls:3.26%
9
27
55
612
—
—
—
—
7
7
56
621
9
19
51
563
Inpatient Hospital
21 [8717]
8.1e-01
8.4e-01
—
1.0e+50
2.7e+00
1.3e+00
7.3e-01
cases:45.31%
controls:26.92%
cases:21.88%
controls:10.80%
—
—
cases:17.19%
controls:0.00%
cases:10.94%
controls:0.78%
cases:22.22%
controls:7.32%
cases:35.00%
controls:20.62%
29
172
35
467
14
69
50
570
—
11
0
53
639
7
5
57
634
14
46
49
582
21
120
39
462
Outpatient Hospital
22 [8756]
9.5e-01
1.1e+00
—
—
—
1.4e+00
1.0e+00
cases:35.94%
controls:17.84%
cases:17.19%
controls:6.26%
—
—
—
—
—
—
cases:17.46%
controls:4.94%
cases:35.00%
controls:16.32%
23
114
41
525
11
40
53
599
—
—
—
11
31
52
597
21
95
39
487
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
1.1e+00
8.9e-01
—
—
—
1.2e+00
1.0e+00
cases:40.63%
controls:18.47%
cases:25.00%
controls:12.05%
—
—
—
—
—
—
cases:26.98%
controls:10.19%
cases:51.67%
controls:27.49%
26
118
38
521
16
77
48
562
—
—
—
17
64
46
564
31
160
29
422
etoricoxib; oral
M01AH05 [21603996]
1.7e+00
1.6e+00
—
—
—
1.2e+00
9.5e-01
cases:23.44%
controls:5.32%
cases:14.06%
controls:3.13%
—
—
—
—
—
—
cases:9.52%
controls:3.03%
cases:21.67%
controls:9.62%
15
34
49
605
9
20
55
619
—
—
—
6
19
57
609
13
56
47
526
Pain in limb
M79.6 [45587063]
1.5e+00
3.1e+00
—
—
—
—
4.9e-01
cases:10.94%
controls:2.66%
cases:15.63%
controls:0.78%
—
—
—
—
—
—
—
—
cases:10.00%
controls:6.36%
7
17
57
622
10
5
54
634
—
—
—
—
6
37
54
545
Supplier / Service Provider
OMOP5117446 [33004]
-1.2e+00
—
-1.0e+50
—
—
—
2.9e+00
cases:9.38%
controls:25.82%
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
cases:13.33%
controls:0.86%
6
165
58
474
—
0
9
64
630
—
—
—
8
5
52
577
Malaise and fatigue
R53 [45553741]
2.6e+00
—
—
—
—
—
—
cases:9.38%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
58
634
—
—
—
—
—
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
6.7e-01
7.1e-01
—
—
1.9e+00
1.4e+00
1.2e+00
cases:35.94%
controls:22.38%
cases:18.75%
controls:10.17%
—
—
—
—
cases:7.81%
controls:1.25%
cases:30.16%
controls:9.87%
cases:51.67%
controls:24.74%
23
143
41
496
12
65
52
574
—
—
5
8
59
631
19
62
44
566
31
144
29
438
ibuprofen
R02AX02 [1588667]
6.7e-01
7.1e-01
—
—
1.9e+00
1.4e+00
1.2e+00
cases:35.94%
controls:22.38%
cases:18.75%
controls:10.17%
—
—
—
—
cases:7.81%
controls:1.25%
cases:30.16%
controls:9.87%
cases:51.67%
controls:24.74%
23
143
41
496
12
65
52
574
—
—
5
8
59
631
19
62
44
566
31
144
29
438
Pain in joint
M25.5 [45586941]
—
1.0e+50
—
—
—
—
2.5e+00
—
—
cases:14.06%
controls:0.00%
—
—
—
—
—
—
—
—
cases:11.67%
controls:1.03%
—
9
0
55
639
—
—
—
—
7
6
53
576
Pharmacy visit
OMOP4822462 [581458]
8.2e-01
1.2e+00
8.1e-01
1.6e+00
9.9e-01
1.5e+00
1.7e+00
cases:92.19%
controls:83.88%
cases:89.06%
controls:71.67%
cases:53.13%
controls:33.49%
cases:10.94%
controls:2.35%
cases:57.81%
controls:33.80%
cases:92.06%
controls:72.77%
cases:98.33%
controls:91.75%
59
536
5
103
57
458
7
181
34
214
30
425
7
15
57
624
37
216
27
423
58
457
5
171
59
534
1
48
Emergency Room Visit
ER [9203]
1.1e+00
1.3e+00
—
1.0e+50
—
1.0e+00
6.6e-01
cases:45.31%
controls:21.60%
cases:25.00%
controls:7.98%
—
—
cases:14.06%
controls:0.00%
—
—
cases:17.46%
controls:7.17%
cases:38.33%
controls:24.40%
29
138
35
501
16
51
48
588
—
9
0
55
639
—
11
45
52
583
23
142
37
440
hydrocortisone
S02BA01 [21605166]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.80%
—
—
—
—
—
—
—
5
5
58
623
—
hydrocortisone aceponate
D07AC16 [21602135]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.80%
—
—
—
—
—
—
—
5
5
58
623
—
hydrocortisone
D07AA02 [21602102]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.80%
—
—
—
—
—
—
—
5
5
58
623
—
hydrocortisone butyrate
D07AB02 [21602106]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.80%
—
—
—
—
—
—
—
5
5
58
623
—
hydrocortisone buteprate
D07AB11 [21602115]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.80%
—
—
—
—
—
—
—
5
5
58
623
—
Endocrinology
46 [38004485]
1.9e+00
—
—
—
—
2.3e+00
1.8e+00
cases:9.38%
controls:1.56%
—
—
—
—
—
—
—
—
cases:11.11%
controls:1.27%
cases:8.33%
controls:1.55%
6
10
58
629
—
—
—
—
7
8
56
620
5
9
55
573
Rheumatology
66 [38004491]
2.2e+00
—
—
1.0e+50
—
—
—
cases:9.38%
controls:1.10%
—
—
—
—
cases:17.19%
controls:0.00%
—
—
—
—
—
—
6
7
58
632
—
—
11
0
53
639
—
—
—
Chronic apical periodontitis
K04.5 [45586691]
2.1e+00
—
—
—
—
—
1.5e+00
cases:9.38%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:2.41%
6
8
58
631
—
—
—
—
—
6
14
54
568
Other and unspecified abdominal pain
R10.4 [45568113]
2.0e+00
—
—
—
—
—
8.2e-01
cases:12.50%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:4.64%
8
12
56
627
—
—
—
—
—
6
27
54
555
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
8.6e-01
—
—
—
—
—
2.0e+00
cases:7.81%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
cases:21.67%
controls:3.61%
5
22
59
617
—
—
—
—
—
13
21
47
561
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.9e+00
—
—
—
—
—
1.0e+00
cases:10.94%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:3.78%
7
11
57
628
—
—
—
—
—
6
22
54
560
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
7.4e-01
1.9e+00
—
—
—
1.3e+00
9.7e-01
cases:15.63%
controls:8.14%
cases:18.75%
controls:3.44%
—
—
—
—
—
—
cases:14.29%
controls:4.14%
cases:31.67%
controls:14.95%
10
52
54
587
12
22
52
617
—
—
—
9
26
54
602
19
87
41
495
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.6e-01
1.4e-01
1.9e+00
—
—
5.3e-01
4.5e-01
cases:20.31%
controls:17.84%
cases:18.75%
controls:16.74%
cases:10.94%
controls:1.88%
—
—
—
—
cases:25.40%
controls:16.72%
cases:45.00%
controls:34.36%
13
114
51
525
12
107
52
532
7
12
57
627
—
—
16
105
47
523
27
200
33
382
furosemide; oral, parenteral
C03CA01 [21601518]
1.8e+00
1.6e+00
—
—
—
1.6e+00
1.5e+00
cases:12.50%
controls:2.35%
cases:10.94%
controls:2.35%
—
—
—
—
—
—
cases:11.11%
controls:2.55%
cases:13.33%
controls:3.26%
8
15
56
624
7
15
57
624
—
—
—
7
16
56
612
8
19
52
563
Low back pain
M54.5 [45553207]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:3.26%
—
—
—
—
—
—
9
19
51
563
Emergency Medicine
93 [38004510]
8.4e-01
1.6e+00
—
—
—
8.6e-01
4.9e-01
cases:10.94%
controls:5.01%
cases:14.06%
controls:3.13%
—
—
—
—
—
—
cases:7.94%
controls:3.50%
cases:21.67%
controls:14.43%
7
32
57
607
9
20
55
619
—
—
—
5
22
58
606
13
84
47
498
General Surgery
2 [38004447]
9.4e-01
1.6e+00
—
1.0e+50
—
7.3e-01
8.5e-01
cases:26.56%
controls:12.36%
cases:15.63%
controls:3.60%
—
—
cases:9.38%
controls:0.00%
—
—
cases:7.94%
controls:3.98%
cases:23.33%
controls:11.51%
17
79
47
560
10
23
54
616
—
6
0
58
639
—
5
25
58
603
14
67
46
515
Infiltration anesthesia
WX110 [2001310767]
8.3e-01
9.6e-01
—
—
—
1.6e+00
3.5e-01
cases:23.44%
controls:11.74%
cases:12.50%
controls:5.16%
—
—
—
—
—
—
cases:17.46%
controls:4.14%
cases:20.00%
controls:14.95%
15
75
49
564
8
33
56
606
—
—
—
11
26
52
602
12
87
48
495
tizanidine; oral
M03BX02 [21604116]
1.3e+00
9.9e-01
—
—
—
—
4.7e-01
cases:25.00%
controls:8.61%
cases:12.50%
controls:5.01%
—
—
—
—
—
—
—
—
cases:15.00%
controls:9.97%
16
55
48
584
8
32
56
607
—
—
—
—
9
58
51
524
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
6.0e-01
9.9e-01
—
—
1.8e+00
1.1e+00
6.2e-01
cases:25.00%
controls:15.49%
cases:23.44%
controls:10.17%
—
—
—
—
cases:9.38%
controls:1.72%
cases:25.40%
controls:10.19%
cases:43.33%
controls:29.21%
16
99
48
540
15
65
49
574
—
—
6
11
58
628
16
64
47
564
26
170
34
412
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
60
575
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
60
574
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
64
622
—
—
—
—
—
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
0
8
64
631
—
—
—
—
—
0
9
60
573
cefadroxil; oral
J01DB05 [21602874]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
64
622
—
—
—
—
—
—
Fracture of lower end of radius
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
—
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
60
575
Pharmacologic abortion
LCH11 [2001306623]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Elevated blood pressure
K85 [2002000612]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
64
627
—
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
8.4e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:10.94%
controls:5.01%
cases:0.00%
controls:2.19%
—
—
—
—
—
—
cases:0.00%
controls:1.43%
—
—
7
32
57
607
0
14
64
625
—
—
—
0
9
63
619
—
amlodipine; oral
C08CA01 [21601747]
2.4e-01
—
-1.0e+50
—
—
—
-3.3e-02
cases:7.81%
controls:6.26%
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
cases:8.33%
controls:8.59%
5
40
59
599
—
0
9
64
630
—
—
—
5
50
55
532
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.66%
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
0
17
64
622
0
7
64
632
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
1.1e+00
—
—
—
-1.0e+50
—
—
cases:7.81%
controls:2.66%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
5
17
59
622
—
—
—
0
5
64
634
—
—
Medical Oncology
90 [38004507]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.03%
cases:0.00%
controls:1.88%
cases:0.00%
controls:1.10%
—
—
—
—
cases:0.00%
controls:2.39%
cases:0.00%
controls:4.12%
0
13
64
626
0
12
64
627
0
7
64
632
—
—
0
15
63
613
0
24
60
558
salmeterol and fluticasone
R03AK06 [21603280]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.41%
0
8
64
631
—
—
—
—
—
0
14
60
568
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.2e-01
1.2e+00
—
—
—
1.1e+00
5.0e-01
cases:15.63%
controls:9.08%
cases:12.50%
controls:4.23%
—
—
—
—
—
—
cases:14.29%
controls:5.25%
cases:23.33%
controls:15.64%
10
58
54
581
8
27
56
612
—
—
—
9
33
54
595
14
91
46
491
Naevus/mole
S82 [2002001046]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
0
7
64
632
—
—
—
—
—
0
8
60
574
losartan and diuretics
C09DA01 [21601834]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
0
9
63
619
—
insulin lispro; parenteral
A10AB04 [21600718]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
0
7
64
632
0
6
64
633
—
—
—
0
7
63
621
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
—
—
—
—
—
-1.0e+50
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:10.00%
controls:2.23%
—
—
—
—
—
0
6
63
622
6
13
54
569
Extended examination of mouth
SAA03 [2001310276]
—
—
—
—
—
—
9.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:3.95%
—
—
—
—
—
—
6
23
54
559
Retained dental root
K08.3 [45543292]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
fluticasone; inhalant
R03BA05 [21603288]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
antibiotics in combination with other drugs
S01AA20 [21603571]
7.2e-01
—
—
—
—
—
5.1e-01
cases:10.94%
controls:5.63%
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:5.15%
7
36
57
603
—
—
—
—
—
5
30
55
552
Basic examination of mouth
SAA02 [2001310275]
6.0e-01
-1.0e+50
—
—
—
—
9.5e-01
cases:15.63%
controls:9.23%
cases:0.00%
controls:3.91%
—
—
—
—
—
—
—
—
cases:28.33%
controls:13.23%
10
59
54
580
0
25
64
614
—
—
—
—
17
77
43
505
combinations of corticosteroids
D07AB30 [21602118]
3.9e-01
—
—
—
—
—
1.7e-01
cases:10.94%
controls:7.67%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:8.59%
7
49
57
590
—
—
—
—
—
6
50
54
532
Root filling of tooth with one root canal
SGB10 [2001310388]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
chlorhexidine
S02AA09 [21605155]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
64
628
—
—
—
—
—
—
Perimetry
XCK00 [2001301380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
4.2e-01
—
-1.0e+50
—
—
7.7e-01
1.5e-01
cases:21.88%
controls:15.49%
—
—
cases:0.00%
controls:1.25%
—
—
—
—
cases:7.94%
controls:3.82%
cases:15.00%
controls:13.23%
14
99
50
540
—
0
8
64
631
—
—
5
24
58
604
9
77
51
505
chloramphenicol
S02AA01 [21605147]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.0e-02
2.4e-01
1.8e+00
—
—
2.6e-01
2.4e-01
cases:17.19%
controls:16.90%
cases:18.75%
controls:15.34%
cases:7.81%
controls:1.41%
—
—
—
—
cases:17.46%
controls:14.01%
cases:35.00%
controls:29.73%
11
108
53
531
12
98
52
541
5
9
59
630
—
—
11
88
52
540
21
173
39
409
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
—
-1.0e+50
—
—
—
-1.0e+50
9.4e-01
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:1.43%
cases:8.33%
controls:3.44%
—
0
5
64
634
—
—
—
0
9
63
619
5
20
55
562
metformin and sitagliptin
A10BD07 [21600772]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
60
575
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
6.5e-01
7.6e-01
—
—
—
6.4e-01
7.4e-01
cases:18.75%
controls:10.80%
cases:15.63%
controls:7.98%
—
—
—
—
—
—
cases:15.87%
controls:9.08%
cases:26.67%
controls:14.78%
12
69
52
570
10
51
54
588
—
—
—
10
57
53
571
16
86
44
496
Opiates [Presence] in Urine
3879-4 [3027008]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
terbinafine; oral
D01BA02 [21601967]
—
-1.0e+50
—
—
—
—
1.5e+00
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.06%
—
0
8
64
631
—
—
—
—
5
12
55
570
Teeth/gum disease
D82 [2002000380]
6.5e-01
—
—
—
—
—
3.5e-01
cases:7.81%
controls:4.23%
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:6.01%
5
27
59
612
—
—
—
—
—
5
35
55
547
Other polyp of sinus
J33.8 [45591556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.2e-01
3.4e-01
1.6e+00
—
8.2e-01
3.7e-01
1.1e-01
cases:26.56%
controls:20.81%
cases:25.00%
controls:19.25%
cases:10.94%
controls:2.35%
—
—
cases:7.81%
controls:3.60%
cases:25.40%
controls:19.11%
cases:43.33%
controls:40.55%
17
133
47
506
16
123
48
516
7
15
57
624
—
5
23
59
616
16
120
47
508
26
236
34
346
hydrocortisone
C05AA01 [21601608]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.96%
—
—
—
—
—
—
—
5
6
58
622
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
beclometasone; inhalant
R03BA01 [21603284]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
0
7
64
632
—
—
—
0
5
63
623
—
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
erythromycin; oral, parenteral
J01FA01 [21602970]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
6
64
633
—
—
—
—
—
0
6
60
576
chloramphenicol
D10AF03 [21602307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Pulmonary Disease
29 [38004472]
5.1e-01
—
-1.0e+50
—
—
—
4.6e-01
cases:7.81%
controls:4.85%
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:10.00%
controls:6.53%
5
31
59
608
—
0
5
64
634
—
—
—
6
38
54
544
hydrocortisone and antiseptics
D07BA04 [21602146]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
64
628
—
—
—
—
—
—
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
0
7
64
632
—
—
—
—
—
0
7
60
575
Lipid panel - Serum or Plasma
100898-6 [1761868]
1.3e+00
—
—
—
-1.0e+50
—
—
cases:9.38%
controls:2.82%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
6
18
58
621
—
—
—
0
5
64
634
—
—
Application of soft bandage
SPAT1211 [2001700312]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Ultrasound examination of mammary glands
HA1AE [2001303886]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
8
64
631
—
—
—
—
—
0
6
60
576
Midwife
Z3232 [2001311563]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
fusidic acid
D09AA02 [21602265]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.75%
—
—
—
—
—
—
5
16
55
566
digoxin; oral, parenteral
C01AA05 [21600234]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.20%
0
7
64
632
0
6
64
633
—
—
—
0
6
63
622
0
7
60
575
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.4e-01
9.5e-01
—
—
—
6.1e-01
9.0e-01
cases:9.38%
controls:6.26%
cases:10.94%
controls:4.54%
—
—
—
—
—
—
cases:9.52%
controls:5.41%
cases:23.33%
controls:11.00%
6
40
58
599
7
29
57
610
—
—
—
6
34
57
594
14
64
46
518
budesonide; inhalant
R03BA02 [21603285]
9.7e-01
—
—
—
—
—
—
cases:9.38%
controls:3.76%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
58
615
—
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
7.3e-01
—
—
—
—
—
6.1e-01
cases:7.81%
controls:3.91%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:5.67%
5
25
59
614
—
—
—
—
—
6
33
54
549
chloramphenicol
G01AA05 [21602367]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
fluticasone furoate
R03BA09 [45893496]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
Cannabinoids [Presence] in Urine
3427-2 [3028300]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
—
9.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.67%
controls:4.98%
—
—
—
—
—
—
7
29
53
553
Open wound of scalp
S01.0 [45592468]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Venous insufficiency (chronic)(peripheral)
I87.2 [45552867]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
60
575
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Malignant neoplasm of breast
C50 [45571518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
—
ramipril; oral
C09AA05 [21601789]
—
—
—
—
—
—
7.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.95%
—
—
—
—
—
—
5
23
55
559
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
1.3e+00
—
—
—
—
—
9.0e-01
cases:9.38%
controls:2.82%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:4.30%
6
18
58
621
—
—
—
—
—
6
25
54
557
Pain, unspecified
R52.9 [45544151]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
propranolol; oral, parenteral
C07AA05 [21601670]
1.2e+00
1.3e+00
—
—
—
1.5e+00
6.6e-01
cases:12.50%
controls:4.23%
cases:7.81%
controls:2.35%
—
—
—
—
—
—
cases:7.94%
controls:1.91%
cases:8.33%
controls:4.47%
8
27
56
612
5
15
59
624
—
—
—
5
12
58
616
5
26
55
556
Hypertension uncomplicated
K86 [2002000613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
Other and unspecified skin changes
R23.8 [45573020]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
—
Open wound of finger(s) without damage to nail
S61.0 [45578756]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
General anaesthesia
WX402 [2001310806]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Other specific arthropathies, not elsewhere classified
M12.8 [45572366]
—
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:90.63%
controls:0.00%
cases:18.75%
controls:0.00%
cases:20.63%
controls:0.00%
—
—
—
—
—
58
0
6
639
12
0
52
639
13
0
50
628
—
Dental caries
K02 [45552906]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Bipolar affective disorder
F31 [45595902]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3.6e-01
8.1e-02
—
—
-1.0e+50
3.4e-01
1.4e-01
cases:17.19%
controls:12.68%
cases:10.94%
controls:10.17%
—
—
—
—
cases:0.00%
controls:1.10%
cases:12.70%
controls:9.39%
cases:30.00%
controls:27.15%
11
81
53
558
7
65
57
574
—
—
0
7
64
632
8
59
55
569
18
158
42
424
mometasone; nasal
R01AD09 [21605051]
5.8e-01
1.2e+00
—
—
—
—
1.2e-01
cases:9.38%
controls:5.48%
cases:9.38%
controls:2.97%
—
—
—
—
—
—
—
—
cases:10.00%
controls:8.93%
6
35
58
604
6
19
58
620
—
—
—
—
6
52
54
530
pH of Venous blood
2746-6 [3012544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
acrivastine; oral
R06AX18 [21603518]
—
—
—
—
—
—
8.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.33%
controls:6.36%
—
—
—
—
—
—
8
37
52
545
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.89%
—
—
—
—
—
—
0
11
60
571
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
6
63
622
—
sodium fluoride; oral
A01AA01 [21600005]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
chloramphenicol
S01AA01 [21603554]
—
—
—
—
—
-1.0e+50
3.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.18%
cases:10.00%
controls:7.04%
—
—
—
—
—
0
20
63
608
6
41
54
541
zopiclone; oral
N05CF01 [21604654]
2.9e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:7.81%
controls:5.95%
—
—
cases:0.00%
controls:0.94%
—
—
cases:0.00%
controls:1.10%
—
—
—
—
5
38
59
601
—
0
6
64
633
—
0
7
64
632
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
Acute vaginitis
N76.0 [45543891]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Gastroenterology
10 [38004455]
1.3e+00
—
—
—
—
—
—
cases:9.38%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
—
—
6
17
58
622
—
—
—
—
—
—
Photography of fundus of eye
XCK10 [2001301381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
64
630
—
—
—
—
—
—
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
60
574
Psychological sympt/compl other
P29 [2002000823]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
hydroxocobalamin
V03AB33 [21605256]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.20%
0
7
64
632
0
6
64
633
—
—
—
0
6
63
622
0
7
60
575
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
6.9e-01
—
—
—
—
—
6.1e-01
cases:10.94%
controls:5.79%
—
—
—
—
—
—
—
—
—
—
cases:18.33%
controls:10.82%
7
37
57
602
—
—
—
—
—
11
63
49
519
cefalexin; oral
J01DB01 [21602870]
5.3e-01
1.2e+00
—
—
—
5.3e-01
7.4e-01
cases:31.25%
controls:21.13%
cases:15.63%
controls:5.32%
—
—
—
—
—
—
cases:11.11%
controls:6.85%
cases:38.33%
controls:22.85%
20
135
44
504
10
34
54
605
—
—
—
7
43
56
585
23
133
37
449
betamethasone
D07AC01 [21602120]
1.1e+00
—
—
—
—
—
1.5e+00
cases:9.38%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:3.78%
6
22
58
617
—
—
—
—
—
9
22
51
560
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Syncope and collapse
R55 [45568141]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
Hand Surgery
40 [38004480]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
59
639
—
—
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
9.2e-01
9.1e-01
—
—
-1.0e+50
6.9e-01
3.6e-01
cases:28.13%
controls:13.46%
cases:10.94%
controls:4.69%
—
—
—
—
cases:0.00%
controls:0.94%
cases:11.11%
controls:5.89%
cases:23.33%
controls:17.53%
18
86
46
553
7
30
57
609
—
—
0
6
64
633
7
37
56
591
14
102
46
480
betamethasone
A07EA04 [21600656]
1.1e+00
—
—
—
—
—
1.5e+00
cases:9.38%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:3.78%
6
22
58
617
—
—
—
—
—
9
22
51
560
Treatment plan or consultation
WZC00 [2001310885]
1.1e+00
—
—
—
—
—
1.6e+00
cases:7.81%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
cases:13.33%
controls:2.92%
5
17
59
622
—
—
—
—
—
8
17
52
565
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
9.8e-01
—
—
—
—
-1.0e+50
9.9e-01
cases:10.94%
controls:4.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
cases:16.67%
controls:6.87%
7
28
57
611
—
—
—
—
0
11
63
617
10
40
50
542
Free T4 and TSH panel - Serum or Plasma
24348-5 [3001019]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Eye symptom/complaint other
F29 [2002000412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
6.1e-01
1.1e+00
—
—
—
9.8e-01
1.1e+00
cases:9.38%
controls:5.32%
cases:10.94%
controls:3.91%
—
—
—
—
—
—
cases:11.11%
controls:4.46%
cases:21.67%
controls:8.76%
6
34
58
605
7
25
57
614
—
—
—
7
28
56
600
13
51
47
531
Basophils [#/volume] in Blood
26444-0 [3006315]
6.1e-01
9.3e-01
—
—
—
9.5e-01
9.1e-01
cases:9.38%
controls:5.32%
cases:9.38%
controls:3.91%
—
—
—
—
—
—
cases:11.11%
controls:4.62%
cases:20.00%
controls:9.11%
6
34
58
605
6
25
58
614
—
—
—
7
29
56
599
12
53
48
529
gabapentin; oral
N02BF01 [955005]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
6
63
622
—
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
64
627
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.2e-01
3.3e-01
1.6e+00
—
7.3e-01
3.6e-01
1.1e-01
cases:26.56%
controls:20.81%
cases:25.00%
controls:19.41%
cases:10.94%
controls:2.35%
—
—
cases:7.81%
controls:3.91%
cases:25.40%
controls:19.27%
cases:43.33%
controls:40.55%
17
133
47
506
16
124
48
515
7
15
57
624
—
5
25
59
614
16
121
47
507
26
236
34
346
Old myocardial infarction
I25.2 [45601025]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
9
60
573
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
6.4e-01
—
—
—
—
—
6.3e-01
cases:9.38%
controls:5.16%
—
—
—
—
—
—
—
—
—
—
cases:16.67%
controls:9.62%
6
33
58
606
—
—
—
—
—
10
56
50
526
Contusion of shoulder and upper arm
S40.0 [45563774]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
60
574
Pollen allergy UNS
J30.19 [2000502595]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
—
—
—
—
—
—
8.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:16.67%
controls:7.90%
—
—
—
—
—
—
10
46
50
536
Osmolality of Urine
2695-5 [3026782]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.09%
—
—
—
—
—
—
5
18
55
564
One-surface restoration
SFA10 [2001310358]
6.1e-01
—
-1.0e+50
—
-1.0e+50
7.3e-01
5.8e-01
cases:14.06%
controls:8.14%
—
—
cases:0.00%
controls:0.78%
—
—
cases:0.00%
controls:0.78%
cases:7.94%
controls:3.98%
cases:18.33%
controls:11.17%
9
52
55
587
—
0
5
64
634
—
0
5
64
634
5
25
58
603
11
65
49
517
betamethasone
C05AA05 [21601610]
1.1e+00
—
—
—
—
—
1.5e+00
cases:9.38%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:3.78%
6
22
58
617
—
—
—
—
—
9
22
51
560
Base excess in Venous blood by calculation
1927-3 [3002032]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
Other healthcare associate professional
Z3229 [2001311561]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
mirabegron; oral
G04BD12 [43534790]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
5.2e-01
8.1e-01
—
—
—
9.1e-01
8.4e-01
cases:9.38%
controls:5.79%
cases:9.38%
controls:4.38%
—
—
—
—
—
—
cases:11.11%
controls:4.78%
cases:21.67%
controls:10.65%
6
37
58
602
6
28
58
611
—
—
—
7
30
56
598
13
62
47
520
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
9
60
573
fluticasone; nasal
R01AD08 [21605050]
4.8e-01
—
—
—
—
7.7e-01
4.1e-01
cases:10.94%
controls:7.04%
—
—
—
—
—
—
—
—
cases:7.94%
controls:3.82%
cases:11.67%
controls:8.08%
7
45
57
594
—
—
—
—
5
24
58
604
7
47
53
535
Other and unspecified arthropathies, Transient arthropathy
7164A [2000405818]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
59
639
—
—
—
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
—
Case Management Agency
251B00000X [38004193]
7.2e-02
9.9e-02
7.4e-01
—
7.8e-01
2.3e-01
3.0e-01
cases:50.00%
controls:48.20%
cases:45.31%
controls:42.88%
cases:26.56%
controls:14.71%
—
—
cases:29.69%
controls:16.28%
cases:49.21%
controls:43.47%
cases:65.00%
controls:57.90%
32
308
32
331
29
274
35
365
17
94
47
545
—
19
104
45
535
31
273
32
355
39
337
21
245
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
-1.0e+50
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:10.00%
controls:2.23%
—
—
—
—
—
0
5
63
623
6
13
54
569
potassium chloride; oral
A12BA01 [21600877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
64
631
—
—
—
—
—
—
dexamethasone
C05AA09 [21601613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
clindamycin; vaginal
G01AA10 [21602372]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
9
60
573
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.0e-01
4.3e-01
—
—
-1.0e+50
-4.0e-02
2.5e-01
cases:17.19%
controls:14.55%
cases:15.63%
controls:10.80%
—
—
—
—
cases:0.00%
controls:0.94%
cases:9.52%
controls:9.87%
cases:33.33%
controls:28.01%
11
93
53
546
10
69
54
570
—
—
0
6
64
633
6
62
57
566
20
163
40
419
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
—
0
10
64
629
—
—
—
—
—
Lateral epicondylitis
M77.1 [45572551]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.7e-01
—
—
—
—
1.2e+00
5.6e-01
cases:7.81%
controls:3.76%
—
—
—
—
—
—
—
—
cases:9.52%
controls:3.03%
cases:13.33%
controls:8.08%
5
24
59
615
—
—
—
—
6
19
57
609
8
47
52
535
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
9
60
573
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.67%
controls:4.12%
—
—
—
—
—
—
7
24
53
558
clopidogrel; oral
B01AC04 [21600989]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
0
8
64
631
—
—
—
—
—
cetirizine; oral
R06AE07 [21603497]
—
—
—
—
—
—
4.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:5.33%
—
—
—
—
—
—
5
31
55
551
Polyp of corpus uteri
N84.0 [45596887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
montelukast; oral
R03DC03 [21603356]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.58%
—
—
—
—
—
—
5
15
55
567
chloramphenicol; ointment
D06AX02 [21602063]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
pH of Urine
2756-5 [3015736]
1.3e+00
-1.0e+50
—
—
—
1.1e+00
3.0e-01
cases:12.50%
controls:3.76%
cases:0.00%
controls:2.50%
—
—
—
—
—
—
cases:7.94%
controls:2.87%
cases:11.67%
controls:8.93%
8
24
56
615
0
16
64
623
—
—
—
5
18
58
610
7
52
53
530
Preventive immunization/medic
-44 [2002000115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
etodolac; oral
M01AB08 [21603948]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
dexbrompheniramine, combinations
R06AB56 [21603469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
General medical examination
Z00.0 [45585791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.41%
—
—
—
—
—
—
0
14
60
568
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
63
623
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.2e-01
3.4e-01
1.6e+00
—
8.2e-01
3.7e-01
1.1e-01
cases:26.56%
controls:20.81%
cases:25.00%
controls:19.25%
cases:10.94%
controls:2.35%
—
—
cases:7.81%
controls:3.60%
cases:25.40%
controls:19.11%
cases:43.33%
controls:40.55%
17
133
47
506
16
123
48
516
7
15
57
624
—
5
23
59
616
16
120
47
508
26
236
34
346
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.25%
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
0
8
64
631
0
9
64
630
—
—
—
—
—
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
6
63
622
—
Localized enlarged lymph nodes
R59.0 [45534459]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Fever
A03 [2002000144]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
64
631
—
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.23%
—
—
—
—
—
—
—
0
14
63
614
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
7.7e-01
—
—
—
—
—
8.9e-01
cases:7.81%
controls:3.76%
—
—
—
—
—
—
—
—
—
—
cases:11.67%
controls:5.15%
5
24
59
615
—
—
—
—
—
7
30
53
552
chlorhexidine, combinations
D08AC52 [21602208]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
64
628
—
—
—
—
—
—
chlorhexidine
D09AA12 [21602275]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
64
628
—
—
—
—
—
—
Periodontal treatment, very brief
SDA01 [2001310326]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.2e-01
3.4e-01
1.6e+00
—
8.2e-01
3.7e-01
1.1e-01
cases:26.56%
controls:20.81%
cases:25.00%
controls:19.25%
cases:10.94%
controls:2.35%
—
—
cases:7.81%
controls:3.60%
cases:25.40%
controls:19.11%
cases:43.33%
controls:40.55%
17
133
47
506
16
123
48
516
7
15
57
624
—
5
23
59
616
16
120
47
508
26
236
34
346
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
0
8
63
620
—
Throat symptom/complaint
R21 [2002000891]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
0
8
64
631
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
cases:0.00%
controls:3.95%
—
—
—
—
0
5
64
634
—
0
23
60
559
Pain localized to other parts of lower abdomen
R10.3 [45534426]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
Chronic gingivitis
K05.1 [45605912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
60
574
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
—
9.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.44%
—
—
—
—
—
—
5
20
55
562
insulin lispro; parenteral
A10AD04 [21600732]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
0
7
64
632
0
6
64
633
—
—
—
0
7
63
621
—
Cough
R05 [45606792]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.94%
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.89%
0
6
64
633
0
7
64
632
—
—
—
—
0
11
60
571
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
combinations of corticosteroids
D07XB30 [21602188]
3.9e-01
—
—
—
—
—
1.7e-01
cases:10.94%
controls:7.67%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:8.59%
7
49
57
590
—
—
—
—
—
6
50
54
532
Lumbago with sciatica
M54.4 [45553205]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
fluocortolone
C05AA08 [21601612]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Dysphagia
R13 [45573013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
6.0e-01
—
—
—
—
—
4.7e-01
cases:21.88%
controls:13.30%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:9.97%
14
85
50
554
—
—
—
—
—
9
58
51
524
ofloxacin; oral, parenteral
J01MA01 [21603008]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
0
5
64
634
—
—
—
—
—
0
5
60
577
Pregnancy
W78 [2002001269]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.86%
0
9
64
630
—
—
—
—
0
6
63
622
0
5
60
577
prednisone
A07EA03 [21600655]
2.0e+00
—
—
—
—
—
—
cases:9.38%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
6
9
58
630
—
—
—
—
—
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.4e+00
—
—
—
—
6.5e-01
4.7e-01
cases:14.06%
controls:3.91%
—
—
—
—
—
—
—
—
cases:7.94%
controls:4.30%
cases:15.00%
controls:9.97%
9
25
55
614
—
—
—
—
5
27
58
601
9
58
51
524
tranexamic acid; oral, parenteral
B02AA02 [21601036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
8
60
574
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
diltiazem; oral
C08DB01 [21601771]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Fear of hypertension
K25 [2002000553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
Pain localized to upper abdomen
R10.1 [45568111]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
63
623
—
Operative extraction of tooth
EBA10 [2001301925]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
64
631
—
—
—
—
—
—
hydrocortisone and antiinfectives
S02CA03 [21605175]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
64
629
—
—
—
—
—
—
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.56%
cases:0.00%
controls:1.10%
—
—
—
—
—
—
cases:0.00%
controls:1.43%
—
—
0
10
64
629
0
7
64
632
—
—
—
0
9
63
619
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
8.6e-01
—
—
—
—
1.5e+00
—
cases:7.81%
controls:3.44%
—
—
—
—
—
—
—
—
cases:7.94%
controls:1.91%
—
—
5
22
59
617
—
—
—
—
5
12
58
616
—
dexamethasone and antiinfectives
S01CA01 [21603652]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
dexamethasone
D10AA03 [21602286]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Total mastectomy
HAC20 [2001303934]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.6e-01
2.1e-01
1.8e+00
—
—
5.9e-01
3.1e-01
cases:18.75%
controls:16.43%
cases:17.19%
controls:14.40%
cases:7.81%
controls:1.41%
—
—
—
—
cases:22.22%
controls:13.69%
cases:36.67%
controls:29.90%
12
105
52
534
11
92
53
547
5
9
59
630
—
—
14
86
49
542
22
174
38
408
Severe psychotic and other severe mental disorders
112 [2001600112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
—
—
—
—
—
1.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:7.22%
—
—
—
—
—
—
5
42
55
540
Hyperlipidaemia, unspecified
E78.5 [45537986]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
9.8e-01
—
—
—
—
-1.0e+50
9.9e-01
cases:10.94%
controls:4.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
cases:16.67%
controls:6.87%
7
28
57
611
—
—
—
—
0
11
63
617
10
40
50
542
chloramphenicol
S03AA08 [21605197]
—
—
—
—
—
-1.0e+50
3.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.18%
cases:10.00%
controls:7.04%
—
—
—
—
—
0
20
63
608
6
41
54
541
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
1.9e+00
—
—
—
—
—
1.5e+00
cases:7.81%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
cases:11.67%
controls:2.92%
5
8
59
631
—
—
—
—
—
7
17
53
565
Feeling depressed
P03 [2002000800]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
0
6
64
633
—
—
—
—
—
0
7
60
575
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
—
2.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:6.53%
—
—
—
—
—
—
5
38
55
544
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
—
1.3e+00
—
—
—
—
5.5e-01
—
—
cases:7.81%
controls:2.35%
—
—
—
—
—
—
—
—
cases:10.00%
controls:6.01%
—
5
15
59
624
—
—
—
—
6
35
54
547
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
6.5e-01
1.5e+00
—
—
—
1.8e+00
9.6e-01
cases:7.81%
controls:4.23%
cases:9.38%
controls:2.35%
—
—
—
—
—
—
cases:9.52%
controls:1.75%
cases:11.67%
controls:4.81%
5
27
59
612
6
15
58
624
—
—
—
6
11
57
617
7
28
53
554
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.25%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
0
8
64
631
0
6
64
633
—
—
—
—
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
0
9
64
630
—
—
—
—
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
—
—
—
—
—
1.0e+00
6.9e-01
—
—
—
—
—
—
—
—
—
—
cases:7.94%
controls:3.03%
cases:16.67%
controls:9.11%
—
—
—
—
—
5
19
58
609
10
53
50
529
temazepam; oral
N05CD07 [21604642]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.92%
—
—
—
—
—
—
5
17
55
565
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.1e-01
—
—
—
—
—
-9.2e-02
cases:7.81%
controls:7.04%
—
—
—
—
—
—
—
—
—
—
cases:13.33%
controls:14.43%
5
45
59
594
—
—
—
—
—
8
84
52
498
12 lead EKG panel
34534-8 [3044889]
2.5e-01
—
—
—
-1.0e+50
—
1.2e-02
cases:10.94%
controls:8.76%
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
cases:16.67%
controls:16.49%
7
56
57
583
—
—
—
0
8
64
631
—
10
96
50
486
Excessive ear wax
H81 [2002000536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
64
626
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
levonorgestrel
G03AC03 [21602499]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
5
63
623
—
Methadone [Presence] in Urine by Screen method
19550-3 [3028707]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Immunohistochemistry procedure
117617002 [4035726]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Chronic hypertension
205 [2001600203]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
6
60
576
Memory test
SPAT1053 [2001700154]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
60
575
Toothache NOS
K08.80 [2000502799]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
7
60
575
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.6e-01
4.5e-01
1.6e+00
—
1.3e+00
5.8e-01
1.1e-01
cases:15.63%
controls:13.62%
cases:17.19%
controls:11.74%
cases:7.81%
controls:1.72%
—
—
cases:7.81%
controls:2.35%
cases:19.05%
controls:11.62%
cases:28.33%
controls:26.12%
10
87
54
552
11
75
53
564
5
11
59
628
—
5
15
59
624
12
73
51
555
17
152
43
430
Inpatient Visit
IP [9201]
4.4e-01
—
—
—
—
—
1.5e+00
cases:7.81%
controls:5.16%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:3.95%
5
33
59
606
—
—
—
—
—
9
23
51
559
Rotator cuff syndrome
M75.1 [45596678]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
Two-surface restoration
SFA20 [2001310359]
6.5e-01
9.7e-01
-1.0e+50
—
-1.0e+50
9.7e-01
2.6e-01
cases:18.75%
controls:10.80%
cases:9.38%
controls:3.76%
cases:0.00%
controls:0.94%
—
—
cases:0.00%
controls:0.78%
cases:9.52%
controls:3.82%
cases:16.67%
controls:13.40%
12
69
52
570
6
24
58
615
0
6
64
633
—
0
5
64
634
6
24
57
604
10
78
50
504
Chronic ischaemic heart disease
I25 [45581765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
64
632
—
—
—
—
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
9
60
573
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.33%
controls:5.15%
—
—
—
—
—
—
8
30
52
552
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.06%
—
—
—
—
—
—
0
12
60
570
doxycycline; oral, parenteral
J01AA02 [21602800]
6.3e-01
—
—
—
—
—
6.6e-01
cases:26.56%
controls:16.12%
—
—
—
—
—
—
—
—
—
—
cases:26.67%
controls:15.81%
17
103
47
536
—
—
—
—
—
16
92
44
490
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
3.0e-01
-6.4e-02
—
—
-1.0e+50
1.3e-01
1.1e-01
cases:18.75%
controls:14.55%
cases:10.94%
controls:11.58%
—
—
—
—
cases:0.00%
controls:1.72%
cases:12.70%
controls:11.31%
cases:35.00%
controls:32.65%
12
93
52
546
7
74
57
565
—
—
0
11
64
628
8
71
55
557
21
190
39
392
Eosinophils [#/volume] in Blood
26449-9 [3013115]
5.2e-01
1.1e+00
—
—
—
8.8e-01
9.9e-01
cases:9.38%
controls:5.79%
cases:10.94%
controls:3.91%
—
—
—
—
—
—
cases:11.11%
controls:4.94%
cases:21.67%
controls:9.28%
6
37
58
602
7
25
57
614
—
—
—
7
31
56
597
13
54
47
528
Polyuria
R35 [45539331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
64
628
—
—
—
—
—
—
Procreative investigation and testing
Z31.4 [45566416]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.5e-01
2.1e-01
1.7e+00
—
—
5.4e-01
2.7e-01
cases:18.75%
controls:16.59%
cases:17.19%
controls:14.40%
cases:7.81%
controls:1.56%
—
—
—
—
cases:22.22%
controls:14.33%
cases:36.67%
controls:30.58%
12
106
52
533
11
92
53
547
5
10
59
629
—
—
14
90
49
538
22
178
38
404
Health maint/preventive medicine
A98 [2002000231]
7.4e-02
2.0e-01
—
—
—
1.4e-01
3.1e-01
cases:25.00%
controls:23.63%
cases:21.88%
controls:18.62%
—
—
—
—
—
—
cases:19.05%
controls:17.04%
cases:45.00%
controls:37.46%
16
151
48
488
14
119
50
520
—
—
—
12
107
51
521
27
218
33
364
chlorhexidine
S03AA04 [21605193]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
64
628
—
—
—
—
—
—
candesartan and diuretics
C09DA06 [21601838]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.72%
—
—
—
—
—
—
0
10
60
572
pregabalin; oral
N02BF02 [955152]
1.3e+00
—
—
—
—
—
1.1e+00
cases:7.81%
controls:2.19%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:3.44%
5
14
59
625
—
—
—
—
—
6
20
54
562
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.75%
—
—
—
—
—
—
0
16
60
566
Overall medication plan or its review
SPAT1252 [2001700353]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
9
60
573
Basophils/Leukocytes in Blood
30180-4 [3022096]
6.1e-01
1.1e+00
—
—
—
9.8e-01
1.1e+00
cases:9.38%
controls:5.32%
cases:10.94%
controls:3.91%
—
—
—
—
—
—
cases:11.11%
controls:4.46%
cases:21.67%
controls:8.76%
6
34
58
605
7
25
57
614
—
—
—
7
28
56
600
13
51
47
531
dexamethasone and antiinfectives
S03CA01 [21605206]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
0
5
64
634
—
—
—
—
0
8
60
574
plastic IUD with progestogen; implant
G02BA03 [21602449]
—
—
—
—
—
-1.0e+50
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:10.00%
controls:2.58%
—
—
—
—
—
0
6
63
622
6
15
54
567
fluticasone furoate; nasal
R01AD12 [21605053]
4.8e-01
—
—
—
—
7.7e-01
4.1e-01
cases:10.94%
controls:7.04%
—
—
—
—
—
—
—
—
cases:7.94%
controls:3.82%
cases:11.67%
controls:8.08%
7
45
57
594
—
—
—
—
5
24
58
604
7
47
53
535
Upper respiratory infection acute
R74 [2002000942]
—
-1.0e+50
—
—
—
—
8.9e-01
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.61%
—
0
9
64
630
—
—
—
—
5
21
55
561
prednisone; oral
H02AB07 [21602735]
2.0e+00
—
—
—
—
—
—
cases:9.38%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
6
9
58
630
—
—
—
—
—
—
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
—
1.6e+00
—
—
—
—
4.5e-01
—
—
cases:7.81%
controls:1.72%
—
—
—
—
—
—
—
—
cases:13.33%
controls:8.93%
—
5
11
59
628
—
—
—
—
8
52
52
530
venlafaxine; oral
N06AX16 [21604745]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
64
630
—
—
—
—
—
—
dexchlorpheniramine, combinations
R06AB52 [21603467]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
64
633
—
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
1.2e+00
—
—
—
—
-1.0e+50
5.3e-01
cases:18.75%
controls:6.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.55%
cases:11.67%
controls:7.22%
12
41
52
598
—
—
—
—
0
16
63
612
7
42
53
540
Angina pectoris, unspecified
I20.99 [2000502407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
scopolamine
A04AD01 [21600499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
64
634
—
—
—
—
—
—
aripiprazole; oral, parenteral
N05AX12 [21604562]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
0
6
64
633
—
—
—
—
0
5
63
623
—
betamethasone
S03BA03 [21605203]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.37%
—
—
—
—
—
—
5
8
55
574
Ileoscopy through colon
UJF30 [2001305028]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
5
60
577
Low back symptom/complaint
L03 [2002000628]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.55%
—
—
—
—
—
—
5
9
55
573
No procedures
SPAT1301 [2001700402]
—
—
—
—
—
—
5.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:4.81%
—
—
—
—
—
—
5
28
55
554
fusidic acid; ointment
D06AX01 [21602062]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.75%
—
—
—
—
—
—
5
16
55
566
Body mass index
60621009 [4245997]
—
—
-1.0e+50
—
—
—
1.0e+50
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
0
9
64
630
—
—
—
5
0
55
582

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
86
4.63
8.76
1.4
1.2
25.26
1.18
u/ml
—
9
40
24
65
4.98
8.76
1.6
1.3
440.00
351.11
titre
—
6
9
27
91
4.10
7.33
1.4
1.2
16.37
13.81
iu/ml
—
7
23
17
61
3.32
4.01
1.8
4.2
4.29
4.98
e9/l
0.59
17
56
15
51
3.43
3.83
1.1
1.3
—
—
—
0
0
9
17
5.86
3.64
1.1
1.1
0.26
0.27
g/l
—
9
17
9
18
5.53
3.49
1.1
1.1
1.26
1.25
g/l
—
9
18
40
258
2.20
2.77
2.9
2.9
5.92
6.19
ph
0.88
24
149
8
19
4.58
2.76
2.1
2.6
—
—
—
0
0
56
420
2.37
2.60
6.1
4.0
—
—
—
0
0
36
228
2.13
2.56
2.8
3.4
22.00
55.91
ng/l
1.23
30
156
32
198
2.09
2.38
10.8
4.7
—
—
—
0
0
47
338
2.07
2.30
3.6
3.3
0.00
0.00
estimate
—
7
69
24
139
2.08
2.09
3.6
3.1
—
—
—
0
0
6
15
4.25
2.08
1.3
1.2
—
—
—
0
0
46
339
1.94
1.99
3.7
3.3
0.00
0.00
estimate
—
6
63
41
292
1.91
1.95
11.2
5.3
25.62
27.87
%
0.66
41
279
45
333
1.90
1.88
3.8
3.2
0.00
0.00
estimate
—
7
71
8
30
2.86
1.78
6.5
4.0
—
—
—
0
0
38
270
1.84
1.77
10.6
12.3
1.19
1.24
inr
0.24
32
226
36
253
1.82
1.73
3.4
3.1
0.00
0.00
estimate
—
7
53
26
167
1.86
1.65
1.9
1.6
19.47
20.30
nmol/l
0.11
21
140
28
185
1.83
1.62
14.8
6.7
—
—
—
0
0
6
20
3.17
1.61
1.0
1.2
—
—
—
0
0
7
27
2.75
1.55
1.7
1.6
—
—
—
0
0
29
197
1.78
1.52
3.7
2.0
125.69
164.68
u/l
0.63
29
189
11
53
2.26
1.47
7.5
1.7
9.75
9.82
g/l
0.02
11
48
30
208
1.74
1.46
4.0
2.9
83.46
54.18
e6/l
0.21
24
155
5
17
3.08
1.38
1.2
1.5
—
—
—
0
0
35
259
1.67
1.31
2.3
2.4
—
—
estimate
—
0
0
34
252
1.65
1.26
2.4
2.1
93.82
101.06
pmol/l
0.47
21
123
41
319
1.64
1.25
9.5
8.3
1.22
1.21
mmol/l
0.12
36
266
15
89
1.86
1.18
1.3
1.6
—
—
—
0
0
24
165
1.67
1.17
5.0
3.8
—
—
—
0
0
25
176
1.63
1.11
4.1
2.9
0.24
0.69
e6/l
0.86
20
125
5
21
2.48
1.11
2.0
1.2
28.40
39.95
nmol/l
—
5
21
13
78
1.81
0.99
1.9
1.7
—
—
—
0
0
26
190
1.57
0.98
2.7
2.8
0.00
0.02
estimate
—
6
46
12
71
1.82
0.95
1.3
1.4
—
—
—
0
0
31
238
1.52
0.93
4.8
3.5
10.94
250.12
e6/l
0.93
24
161
27
202
1.53
0.91
4.6
3.4
—
—
—
0
0
8
48
1.75
0.82
2.0
11.4
1.24
1.44
mmol/l
—
8
48
0
27
0.00
0.79
0.0
1.6
—
279.35
—
0
17
9
54
1.76
0.78
1.3
1.7
—
—
—
0
0
11
68
1.73
0.77
2.1
1.6
—
—
—
0
0
7
43
1.69
0.69
1.7
1.1
—
—
—
0
0
12
79
1.62
0.67
1.2
1.7
—
—
—
0
0
8
50
1.67
0.64
5.1
2.9
—
—
—
0
0
46
402
1.38
0.62
5.3
4.1
—
33.60
—
0
5
6
34
1.83
0.60
2.2
1.5
15.92
23.51
iu/l
—
6
28
31
258
1.35
0.55
1.8
2.1
—
—
—
0
0
26
212
1.35
0.52
3.5
3.3
208.56
54.97
mg/l
0.48
17
131
69
660
1.67
0.49
19.3
12.6
—
—
—
0
0
11
77
1.50
0.49
1.2
1.5
—
—
—
0
0
68
647
1.63
0.46
25.5
16.9
3.97
3.96
mmol/l
0.12
68
636
5
31
1.66
0.44
2.4
15.7
0.36
0.73
%
—
5
31
11
79
1.46
0.43
2.3
2.7
4.36
6.19
umol/l
0.87
11
71
5
33
1.55
0.42
1.2
1.1
—
—
—
0
0
18
143
1.34
0.42
2.4
1.5
1.85
2.55
g/l
—
8
87
0
15
0.00
0.41
0.0
3.4
—
64.15
—
0
15
9
65
1.44
0.41
2.9
11.3
-2.42
1.22
mmol/l
—
9
55
5
35
1.46
0.40
2.6
5.3
—
—
—
0
0
5
36
1.42
0.39
2.6
13.4
24.16
24.46
mmol/l
—
5
36
6
88
0.65
0.35
1.0
1.2
—
—
—
0
0
25
216
1.24
0.31
5.0
4.1
39.49
8.93
mg/mmol
0.60
16
130
11
86
1.33
0.28
1.3
1.2
—
—
—
0
0
21
182
1.21
0.25
2.2
2.1
—
—
—
0
0
67
646
1.39
0.24
25.7
16.7
139.37
139.77
mmol/l
0.68
67
635
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
20
175
1.20
0.21
1.2
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.8
—
67.74
—
0
12
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
7
59
1.21
0.18
4.7
1.6
—
—
—
0
0
9
82
1.11
0.15
2.9
9.8
101.33
104.35
mmol/l
—
9
82
16
143
1.15
0.13
3.9
5.6
—
—
—
0
0
24
222
1.12
0.12
2.8
2.3
58.63
94.86
u/l
0.68
24
203
19
174
1.12
0.11
3.4
3.0
—
—
—
0
0
5
44
1.15
0.10
3.4
12.6
—
—
—
0
0
6
57
1.06
0.09
2.0
1.4
—
—
—
0
0
20
190
1.07
0.04
4.3
3.3
0.00
0.00
estimate
—
5
66
27
263
1.04
0.01
3.2
3.4
—
—
—
0
0
53
528
1.01
0.00
29.5
17.8
13.47
13.60
%
0.38
53
522
12
115
1.05
0.00
4.3
3.5
0.82
0.82
mmol/l
0.01
12
115
11
114
0.96
0.00
1.4
2.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
154.07
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
12.29
—
0
7
0
7
0.00
-0.00
0.0
2.6
—
0.86
—
0
7
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
8.54
—
0
5
5
56
0.89
-0.00
4.2
3.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
17.9
—
1019.44
—
0
9
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
58
0.85
-0.00
3.0
4.5
7.38
7.39
ph
—
5
37
0
7
0.00
-0.00
0.0
2.6
—
12.57
—
0
7
0
6
0.00
-0.00
0.0
2.7
—
31.83
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
82.40
—
0
5
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
62
0.96
-0.00
1.3
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
15.04
—
0
7
5
49
1.02
-0.00
1.2
2.6
2.94
5.54
ug/l
—
5
42
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint M13_OTERSPECARTHR and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have M13_OTERSPECARTHR.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: M13_OTERSPECARTHR – Other specific arthropathies

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data